
HER2+ Breast Cancer
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News




Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Trastuzumab emtansine has been approved in the UK for the adjuvant treatment of patients with HER2-positive early breast cancer.

Katherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer treatment.

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Anne Favret, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Global access to neratinib has increased with the drug now being made commercially available in Singapore.
















Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5














































